BEUDAMED
    FDA Adverse Event Injury Summary report: N

    EDISON

    MDR report key: 23550298 · Received November 13, 2025

    Report

    Report Number
    3027664504-2025-00033
    Event Type
    Injury
    Date Received
    November 13, 2025
    Date of Event
    August 25, 2025
    Report Date
    November 13, 2025
    Manufacturer
    HISTOSONICS, INC.
    Product Code
    QGM
    UDI-DI
    00850006962006
    PMA / PMN Number
    K233466
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    CA, US
    Reporter Occupation
    PHYSICIAN
    Health Professional
    Yes

    Narratives

    Additional Manufacturer Narrative · 0

    ALTHOUGH HISTOSONICS WAS INITIALLY MADE AWARE OF THIS ADVERSE EVENT ON OCTOBER 2, 2025, INFORMATION REGARDING HOSPITAL ADMISSION WAS NOT RECEIVED UNTIL OCTOBER 14, 2025. NO DEVICE MALFUNCTIONS OR OTHER NOTEWORTHY EVENTS WERE ALLEGED TO HAVE OCCURRED DURING THE CASE. HISTOSONICS HAS IMPLEMENTED HISTOTRIPSY TO ENABLE THE MECHANICAL DESTRUCTION OF TISSUE WITHIN A DEFINED TREATMENT VOLUME, WHILE MITIGATING THE RISK OF THERMAL INJURY TO TISSUE ALONG THE ACOUSTIC PATHWAY. HOWEVER, RESIDUAL RISKS OF THERMAL INJURY REMAIN AND ARE DISCLOSED IN THE DEVICE LABELING AND TRAINING MATERIALS. THE FOLLOWING WARNINGS ARE INCLUDED IN THE DEVICE LABELING TO ADVISE USERS OF THESE RISKS. DELIVERING THERAPEUTIC ULTRASOUND WHEN ANATOMICAL OR OTHER OBSTRUCTIONS (BONE, CARTILAGE, LUNG, DIGESTIVE GAS, ETC.) ARE ALONG THE ACOUSTIC PATHWAY CAN RESULT IN THERMAL INJURY TO NON-TARGETED TISSUES. USE IMAGING AND THE ACOUSTIC FIELD INDICATOR OVERLAY TO ASSESS AND MINIMIZE OBSTRUCTION PRIOR TO FINALIZING THE TREATMENT PLAN. MUSCLE LAYER DEPTH IS ONE OF THE MEASUREMENTS USED BY THE SOFTWARE TO CALCULATE SAFE TREATMENT PARAMETERS. FAILURE TO CORRECTLY MARK THE MUSCLE LAYER CAN RESULT IN UNINTENDED THERMAL INJURY. WHEN ANY OF THE FOLLOWING OCCUR, CUMULATIVE THERMAL EXPOSURE WILL INCREASE, ELEVATING THE RISK OF THERMAL INJURY TO THE SKIN, BODY WALL, OR OTHER TISSUES: USER-INITIATED REPETITION OF TASKS WHERE ENERGY IS DELIVERED, SUCH AS RE-PERFORMING IN VIVO CALIBRATION OR ESTABLISHING VOLTAGE SETTINGS FOR ANY OF THE SEVEN PLAN POINTS, PROLONGED ENERGY DELIVERY WHEN ESTABLISHING VOLTAGE SETTINGS, EXCEEDING THE VOLTAGE NECESSARY TO SUSTAIN THE BUBBLE CLOUD, ANATOMICAL OR OTHER STRUCTURES (E.G., RIBS, LUNG, BOWEL) LOCATED ANYWHERE WITHIN THE ACOUSTIC PATHWAY - INCLUDING POST-FOCAL - WITH HIGHER ABSORPTION AND/OR REFLECTION, ANATOMY OR OBSTRUCTIONS (E.G., BOWEL GAS) WITHIN THE PRE-FOCAL ACOUSTIC PATHWAY THAT REQUIRE HIGHER VOLTAGE SETTINGS TO SUSTAIN THE BUBBLE CLOUD, MULTIPLE TREATMENTS WITHIN THE SAME PROCEDURE WHEN ACOUSTIC PATHWAYS MAY INTERSECT AND/OR PASS THROUGH PREVIOUSLY TREATED ZONES. NOTE THE FOLLOWING SYSTEM BEHAVIORS, WHICH FURTHER INFORM ENERGY DELIVERY CONSIDERATIONS RELATED TO CUMULATIVE THERMAL EXPOSURE: THE SYSTEM APPLIES A THERMALLY SAFE PROTOCOL TO PERFORM AUTOMATED TREATMENT BUT DOES NOT ACCOUNT FOR THE ENERGY DELIVERED DURING TREATMENT PLANNING, WHILE THE MECHANISM OF ACTION IS NON-THERMAL, LOCALIZED TEMPERATURE RISE WITHIN THE ACOUSTIC PATHWAY WILL OCCUR DURING ENERGY DELIVERY/DEPOSITION[?]PARTICULARLY IN TRANSITION ZONES SUCH AS THE SKIN, BODY WALL, OR IN TISSUES THAT ABSORB/OBSTRUCT ULTRASOUND ENERGY, SUCH AS BONE, THE SYSTEM ENFORCES A 30-SECOND TIMEOUT WHEN ESTABLISHING A VOLTAGE SETTING BUT DOES NOT LIMIT CUMULATIVE ENERGY DELIVERY. WHILE SOME REPETITION OR EXTENDED ENERGY DELIVERY MAY BE REQUIRED TO VERIFY A SUSTAINED BUBBLE CLOUD, PROCEDURAL GOALS SHOULD BE MET USING THE MINIMUM VOLTAGE AND DURATION NECESSARY, WHILE LIMITING OR PREVENTING UNNECESSARY REPETITION. WHEN CLINICALLY APPROPRIATE, USERS MAY CONSIDER PAUSING BETWEEN ENERGY DELIVERY TASKS TO ALLOW TISSUE COOLING BEFORE PROCEEDING. IN ADDITION, THE FOLLOWING WARNING RELATED TO DELIVERY OF HISTOTRIPSY RELATIVE TO THE LUNGS IS INCLUDED IN THE DEVICE LABELING. DELIVERING THERAPEUTIC ULTRASOUND WHEN LUNG TISSUE IS LOCATED ALONG THE ACOUSTIC PATHWAY CAN RESULT IN LOCALIZED PULMONARY TISSUE EDEMA OR HEMORRHAGE. USE IMAGING AND THE ACOUSTIC FIELD INDICATOR OVERLAY TO ASSESS IF LUNG IS ALONG THE ACOUSTIC PATHWAY PRIOR TO FINALIZING THE TREATMENT PLAN. CONSIDER USING ALTERNATE ANGLES TO AVOID LUNG TISSUE.

    Description of Event or Problem · 0

    ON (B)(6) 2025, AN 80-YEAR-OLD FEMALE PATIENT WITH COLORECTAL CANCER, RECEIVED TWO OVERLAPPING HISTOTRIPSY TREATMENTS TO A SINGLE 5-6 CM DIAMETER LESION IN LIVER SEGMENT 7/8 FOR A TOTAL PLANNED TREATMENT VOLUME (PTV) OF 62.8 CC. AT THE TIME OF THE HISTOTRIPSY PROCEDURE, THE PATIENT WAS RECEIVING FOLFIRI AND AVASTIN FOR THEIR SYSTEMIC DISEASE. PER THE TREATING PHYSICIAN, THE PTV WAS LOCATED HIGH IN THE DOME OF THE LIVER, NEAR THE LUNG BASE, WITH RIB OBSTRUCTION IN THE ACOUSTIC PATHWAY. THE PHYSICIAN DELIVERED TWO OVERLAPPING TREATMENTS IN THE LEFT LATERAL DECUBITUS POSITION WITH SOME OVERLAP OF THE ACOUSTIC PATHWAY. FOLLOWING PLANNING PULSES AND AT THE REVIEW TREATMENT PARAMETERS SCREEN (INCLUDING TREATMENT TIME), THE PHYSICIAN ELECTED TO MODIFY/ADJUST THE TREATMENT PARAMETERS, INCLUDING THE DEPTH (E.G., MARK DISTANCE FROM THE BODY WALL TO TARGET), TO SHORTEN THE PROCEDURE TIME, SO THAT EACH HISTOTRIPSY TREATMENT OF THE PRESCRIBED PTV WAS APPROXIMATELY 50% SHORTER IN TIME. POST-PROCEDURE, SOME SKIN REDNESS WITH BLISTERING OR "BURN" WAS OBSERVED. THE PATIENT WAS TREATED WITH OTC CREAM AND WOUND DRESSING. POST-PROCEDURE CT IMAGING LATER THAT DAY SHOWED TREATMENT CHANGES AT THE LOCATION DEEP TO THE SKIN, ALONG THE CHEST WALL AND ADJACENT LUNG IN THE ACOUSTIC PATHWAY. FOLLOWING THE PROCEDURE, THE PATIENT HAD SOME PAIN AND STARTED TO DEVELOP A SKIN ULCER. ON S(B)(6) 2025, THE PATIENT PRESENTED WITH RIGHT UPPER QUADRANT PAIN AND ULCERATION WITH SKIN SLOUGHING. THE WOUND WAS PURULENT AND TREATED WITH BACTRIM AND AUGMENTIN. IMAGING SHOWED A TRACT EXTENDING FROM THE SKIN TO THE LIVER WITH BODY WALL EDEMA AND PLEURAL FLUID; THORACENTESIS WAS PERFORMED AND YIELDED SEROUS FLUID WITH PARTICLES. THE PATIENT WAS LATER ADMITTED ON (B)(6) 2025, FOR WORSENING INFECTION. BROAD-SPECTRUM ANTIBIOTICS AND TOPICAL SAFACILIN WERE STARTED. A CHEST TUBE WAS PLACED FOR SUSPECTED EMPYEMA BUT REMOVED AFTER STERILE RESULTS. THE PATIENT WAS DISCHARGED ON IV ANCEF FOR MSSA. AT FOLLOW-UP, THE WOUND SHOWED GRADUAL IMPROVEMENT WHILE CONTINUING FOLFIRI AND AVASTIN. ON (B)(6) 2025, THE PATIENT WAS RE-HOSPITALIZED FOR WORSENING DRAINAGE; PLASTIC SURGERY EVALUATED BUT DEEMED HER NOT A SURGICAL CANDIDATE. THE PATIENT WAS DISCHARGED ON (B)(6) 2025.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    1882587 EDISON Focused ultrasound system for non-thermal, mechanical tissue ablation QGM HISTOSONICS, INC. 00850006962006

    Patients

    Seq Age Sex Outcome Treatment
    1 80 YR Female Required Intervention| H